- 2 months ago
19 August 2026
Every year, events like the International Diabetes Federation Western Pacific Region Congress give us a moment to reflect on where healthcare is heading. This year, one theme is impossible to ignore: artificial intelligence and, increasingly, its role in healthcare prediction.
AI has dominated healthcare conversations of late. At times, it feels like we’re inundated with it, buzzing around our feeds and inboxes. But as that conversation matures, the question is changing.
We’re moving beyond asking whether AI will change healthcare and towards asking where it can genuinely improve care – and what it will take to do that responsibly. In my view, diabetes is one of the clearest examples of that transition.
For years, innovation in diabetes care has focused on generating more information. Today, the opportunity is increasingly about helping healthcare professionals and people living with diabetes make better use of that information.
Predictive technologies are one practical example. Used effectively, they have the potential to help anticipate risk rather than simply respond to it, but the real opportunity is in moving healthcare from responding to what has already happened towards anticipating what may happen next, while keeping human judgement at the centre.
In the lead-up to the International Diabetes Federation Western Pacific Region Congress (IDF-WPR) being held in Melbourne this week, Roche Diagnostics worked with researchers, clinicians, and people living with diabetes to explore what predictive care could mean in practice.
These conversations will continue at the Congress, including through a symposium examining how predictive technologies could help reshape diabetes care.
One idea keeps coming through: the promise of predictive healthcare isn’t just better algorithms. It’s the opportunity to help solve one of healthcare’s oldest challenges – making better decisions earlier.
Diabetes provides a particularly useful lens through which to consider that opportunity. Continuous glucose monitoring has transformed the amount and quality of information available to people living with diabetes and their healthcare teams. The challenge now isn’t just generating more data. It’s interpreting that information in ways that are useful, timely and actionable.
That’s where AI and predictive approaches have the potential to add value by identifying patterns, recognising changes and helping turn complex information into insights that can support decision-making. But that opportunity comes with responsibility.
Innovation only becomes meaningful when it is supported by robust evidence, integrated into care in ways that work for healthcare professionals, and trusted by the people whose lives it aims to improve.
For industry, our role doesn’t end with developing new technologies. It extends to generating evidence, supporting implementation, listening to healthcare professionals and people living with chronic conditions, and working with health systems to understand where innovation genuinely adds value.
We’ve spent a great deal of time talking about what AI might make possible. The next challenge is demonstrating how that potential can be translated responsibly into everyday healthcare.
That means moving beyond technology for technology’s sake. Healthcare innovation needs to solve a meaningful problem, fit within real-world care, and earn confidence through evidence and experience.
As the diabetes community gathers at IDF-WPR, the discussion around prediction offers a glimpse of a much broader shift taking place across healthcare. The lessons being learned in diabetes about data, evidence, implementation, trust, and collaboration will be relevant well beyond a single disease area.
If we get this right, the most important story about AI in healthcare won’t be the technology itself, it will be what that technology enables: earlier insight, better informed decisions, and care that can become increasingly proactive while keeping human judgement at its centre.
For me, that is the real promise of predictive healthcare: not replacing the expertise of healthcare professionals, or the human connection at the heart of care, but giving people better information earlier to help them make better decisions.
Technology will continue to evolve. Our responsibility is to ensure the way we use it evolves with the same ambition and the same care.
As IDF-WPR brings clinicians, researchers, people living with diabetes, and industry together, that’s a conversation worth having.
Anand Vairavan is Managing Director of Roche Diagnostics Australia.